Overview

Oxis International, Inc. is engaged in the development of immunotherapies for the treatment of cancer.

Candidate Phase
R&D GMP Manufacturing Phase 1 Phase 2
OXS-1550 Acute lymphoblastic leukemia & Non-Hodgkin's lymphoma
R&D Phase complete
GMP Manufacturing Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
OXS-1650 Refractory Epithelial Ovarian cancer
R&D Phase complete
GMP Manufacturing Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
OXS-3550 B-cell malignancies
R&D Phase complete
GMP Manufacturing Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
OXS-4550 Triple Negative Breast & other TAG-72+ cancers
R&D Phase complete
GMP Manufacturing Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
OXS-1750 Multiple Myeloma & Secondary Osteolytic Lesions
R&D Phase in progress
GMP Manufacturing Phase not started
Phase 1 Phase not started
Phase 2 Phase not started
OXS-1950 FZD7+ Taxol Refractory Solid Tumors
R&D Phase in progress
GMP Manufacturing Phase not started
Phase 1 Phase not started
Phase 2 Phase not started
OXS-2050 Triple Negative Breast & other ICAM+ cancers
R&D Phase in progress
GMP Manufacturing Phase not started
Phase 1 Phase not started
Phase 2 Phase not started

Treating Non-Hodgkin's lymphoma

OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550 and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.

Treating triple-negative breast cancer

Our lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer. In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.

Treating multiple myeloma

Our lead drug candidate, OXS-4235, also a small molecule therapeutic candidate, targets the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone.

Executive Team

Our executive team possesses extensive experience and passion within the biotech industry, which can be seen through their work at our company.

View Management Team »

View Board of Directors »

View Scientific Advisors »

Partnerships

Our strong partnerships with leading universities help solidify our immunotherapy solutions.

View Partnerships »

Careers

We’re always looking for talented individuals to join our team and make an impact in our industry with their expertise.

View Career Opportunities »